Removal of B Cell Epitopes Assay

Therapeutic recombinant protein drugs have become an important direction in the development of modern medicine, but the immunogenicity of foreign proteins makes them unable to perform their functions in the treatment of many diseases. Creative Biolabs provides customers with comprehensive drug development testing services. We identify B-cell epitopes on proteins through various experiments and eliminate their immunogenicity by mutations, to make our customers' protein products safer and more effective.

Drug Immunogenicity

Many non-human proteins have been increasingly developed and applied to the biomedical field due to their high specificity and remarkable efficacy for some diseases. However, these proteins are recognized by the immune system as foreign invasions in the human body. In the use of such protein drugs for patients, the treatment cycle will be affected by the production of antibodies, and even produce severe side effects, which will endanger the lives of patients. Many current studies have shown that removal of B-cell epitopes is a practical approach for making less immunogenic protein therapeutics from non-human functional proteins. This approach requires grouping of the epitopes to identify targets for de-immunization followed by quantitative analysis of the decrease in affinity produced by the mutations in B cell epitopes.

Removal of B Cell Epitopes

There are several necessary prerequisites for reducing immunogenicity by removing B-cell epitopes on protein surfaces. First, the presence of antigenic hot spots on a protein surface that more frequently serve as epitopes to the antibodies than other surface regions of the protein. Second, the antigenic structural signatures of the hot spots can be altered so that they are less immunogenic by point mutations in amino acids located at these sites, these point mutations can be combined into a functional protein that induces a diminished antibody response in vivo.

There have been some reports of successful removal of B cell epitopes to reduce the immunogenicity of foreign proteins used in biopharmaceuticals. For example, a significant reduction in the antigenicity of streptokinase is achieved by site-directed mutagenesis of antibody epitopes. Although removal of B cell epitopes does not completely eliminate antibody responses, mutants with antibody epitope modifications (such as CM79) show delayed polyclonal antibody responses in both mice and patients.

Creative Biolabs carefully designs every step of the drug's deimmunization process, taking into account the nature of B cell epitopes and their interaction with antibodies. The advantage of deimmunization based on B cell epitopes is that it also eliminates binding to existing antibodies and is independent of T cell epitopes. Our services are also very useful for the de-immunization of other exogenous proteins. We can analyze and identify human antibody responses in a similar way.

If you have any questions about our manufacturability assessment service, you can contact us by email or send us an inquiry to find a complete solution.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: